What is KLOW?

KLOW is a four-peptide research blend: the copper complex GHK-Cu, the tripeptide KPV, the 15-residue BPC-157 and the seven-residue TB-500, supplied together in one vial. No company or paper defined it. The name reads as GLOW (GHK-Cu, BPC-157 and TB-500) with a K added for KPV, and suppliers use it as a shared label.

Because KLOW is a mixture, every scientific fact about it is a fact about one of its parts. Each component has its own origin, identifier set and literature, and each has its own Australian legal status. KLOW 80mg is in stock with a batch certificate.

KLOW has no studied mechanism of its own; the published mechanisms belong to its four components and were measured in cells and animals.

• BPC-157. In rat tendon fibroblasts, BPC-157 increased cell outgrowth, survival under hydrogen peroxide stress and migration, and the authors linked this to the FAK-paxillin pathway. ^[9] A later study in human endothelial cells reported activation of the VEGFR2-Akt-eNOS pathway. ^[10]
• TB-500. TB-500 is the acetylated fragment Ac-LKKTETQ. ^[11] Anti-doping chemists describe LKKTETQ, residues 17 to 23 of thymosin beta-4, as the site in the parent protein responsible for actin binding. ^[12]
• GHK-Cu. GHK forms complexes with copper(II), and a 1980 study reported that it raised copper uptake into cultured hepatoma cells. ^[13] In fibroblast cultures, the copper complex raised collagen synthesis from concentrations of 10^-12 to 10^-11 M. ^[14]
• KPV. In human intestinal epithelial cells and T cells, nanomolar KPV inhibited NF-kappaB and MAP kinase signalling, and the study found KPV enters cells through the PepT1 transporter. ^[15] A review notes KPV lacks the sequence needed to bind known melanocortin receptors. ^[16]

No study has measured how these pathways behave when the four peptides are present together. Any claim that the components act on each other inside a KLOW vial has no published data behind it.

KLOW has no single structure. It is four separate molecules, and the identifier table below lists each one as recorded in PubChem, with its Australian and sport status.

Identifiers come from PubChem. ^[4][5][6][7] Legal columns come from the Poisons Standard and the WADA list, which we checked for each component on 29 September 2026. ^[2][8]

Two details matter when you read a certificate for a blend. First, PubChem holds more than one GHK-Cu record, and CID 71587328 is the 1:1 copper complex. Copper makes up about 15.8% of that molar mass (63.55 of 402.92), so a lab can report GHK and copper as separate figures inside one GHK-Cu result. Second, the label mass hides the molecule count. Blend listings we read in September 2026 describe the 80mg as 50mg GHK-Cu plus 10mg each of the other three. On that split, GHK-Cu supplies about 124 of 172 micromoles in the vial (72%), and BPC-157 about 7 (4%), because GHK-Cu is small and BPC-157 is large.

Research has examined KLOW's components one by one; no study has examined the blend. Our PubMed count on 29 September 2026 returned 0 records for all four components together, 0 for GHK-Cu with KPV, 1 for BPC-157 with KPV (a pharmacy compounding review), and 12 for BPC-157 with TB-500 or thymosin beta-4, most of them reviews. ^[1] A 2026 scoping review of emerging peptides, including BPC-157, TB-500 and GHK-Cu, found that 67% of publications used preclinical animal models. ^[17]

The 2026 rat study is the closest the literature gets to a blend. It gave BPC-157 and TB-500 separately and in combination after Achilles tendon repair, and it did not include GHK-Cu or KPV. ^[3]

The KLOW evidence does not show what the blend does, because nobody has published a study of the blend. Four limits follow from the record.

1. No combination data. No published work tests the four components together, so interactions, stability in a shared solution and relative contribution are all unmeasured. ^[1]
2. Human data are thin for every component. For BPC-157, a 2025 review counted three small pilot studies in humans and noted that large trials are lacking. ^[22] For GHK-Cu, a 2026 systematic review describes the human literature as thin and fragmented, mostly small trials of facial creams. ^[23] For KPV, the published work we found is in cells and mice. ^[15][19]
3. TB-500's human trials used a different molecule. The controlled human trials concern full-length thymosin beta-4, a 43-residue protein, ^[24] and the 2010 phase 1 study gave that protein intravenously to 40 healthy volunteers. ^[25]
4. Market material varies. A 2023 analysis of products sold online as TB500 and TB1000 found their content was not systematically consistent with their descriptions. ^[26] The same risk applies to a four-part vial, which is why a batch certificate has to cover each component.

No study of KLOW has reported adverse events, because no study of KLOW exists. The component studies reported the following.

• BPC-157, human pilots. An uncontrolled pilot in 2 adults at a private clinic reported no measurable effects of intravenous BPC-157 on tested heart, liver, kidney, thyroid and blood glucose markers, and recorded side effects in neither participant. ^[27] A pilot in 12 women with interstitial cystitis reported that no one dropped out and no adverse events were reported. ^[28]
• TB-500. We found no study of the TB-500 fragment reporting adverse events in humans. In the phase 1 trial of full-length thymosin beta-4 in 40 healthy volunteers, adverse events were infrequent and mild or moderate, with no serious adverse events. ^[25]
• GHK-Cu. We found no study abstract reporting adverse events for GHK-Cu. In a human keratinocyte skin-irritation model, GHK-Cu was not cytotoxic. ^[29] A 2026 review states that rigorous human safety data for unapproved peptides are scarce. ^[30]
• KPV. We found no published study reporting adverse events for KPV.
• Regulator reports. The TGA lists adverse events it has received for unapproved peptide products, including severe allergic reactions requiring adrenaline and hospitalisation, and systemic inflammatory response syndrome requiring hospital management. Its examples of such products include BPC-157, GHK-Cu and TB-500. ^[31]

These are the published observations, each tied to its own model and population. None of them describes the combined vial.

KLOW is not an approved medicine in Australia, and two of its components are scheduled. The June 2026 Poisons Standard (F2026L00633), in force from 1 June 2026, lists BPC-157 and TB-500 in Schedule 4 (prescription only). Both also appear in Appendix D clause 5, which makes possession without authority an offence. ^[2]

The instrument answers the mixture question directly. Section 7 says a reference to a substance includes "a preparation or admixture containing any proportion of the substance". ^[2] On that wording, the BPC-157 and TB-500 entries reach a vial that contains them alongside GHK-Cu and KPV.

The other two components differ. KPV has no entry in the instrument. GHK-Cu is not named, and Schedule 4 carries a general entry for copper compounds for human use with exceptions; we have not settled whether that entry applies to GHK-Cu. ^[2] The TGA names BPC-157, GHK-Cu and TB-500 as examples of unapproved peptide products that it has not evaluated for safety, quality or effectiveness. ^[31] Our guide to Australian peptide law and the Poisons Standard explains what each schedule means.

For sport, the WADA 2026 Prohibited List took effect on 1 January 2026. It names BPC-157 in class S0 and indexes TB-500 in class S2, and both classes are prohibited at all times. ^[8] Sport Integrity Australia lists thymosin beta-4, with TB-500 as another name, under S2.3. ^[24] A KLOW vial therefore contains two substances banned in sport. GHK-Cu and KPV are not named on the List, and S0 covers substances with no current governmental approval for human therapeutic use. ^[8]

KLOW is the largest of three common blends built around BPC-157 and TB-500. GLOW adds GHK-Cu to that pair, and KLOW adds KPV on top of GLOW.

Each component is also sold on its own: BPC-157 5mg from A$81, TB-500 10mg from A$98, GHK-Cu 50mg from A$58 and KPV 10mg from A$58. Single vials let a lab attribute an effect to one molecule, which a blend cannot do. Our comparison of BPC-157 and TB-500 covers the shared core of all three blends, the GHK-Cu explainer covers the copper complex, and the peptide stacks range lists every blend we carry.

No published stability study covers KLOW, so storage follows its least stable component and standard practice for lyophilised peptides: keep sealed vials cold, dry and dark, and keep a reconstituted solution cold with as little freezing and thawing as possible.

The component data give some bounds. A preformulation study found GHK-Cu stable in water and in pH 4.5 to 7.4 buffers for at least two weeks at 60 °C, and susceptible to hydrolytic cleavage under basic and oxidative stress. ^[32] Rat studies of BPC-157 dissolved it in saline with no carrier. ^[33] For a four-component vial, dissolve the whole cake completely before drawing any volume, because an undissolved component changes the ratio in solution.

For laboratory reconstitution we stock BAC Water (sterile water with 0.9% benzyl alcohol) in 3ml vials for A$8, and dilute acetic acid in 3ml vials for A$8. Label the vial with the solvent, the volume and the resulting mg per mL of total peptide. Our peptide storage guide covers temperature, light and labelling, and our reconstitution guide covers concentration arithmetic.

Peptides Collective sells KLOW for laboratory research use only, in an 80mg vial for A$168. Stock ships from Western Australia with tracking.

Every batch is tested by an independent lab before it goes on sale, for purity by HPLC and identity by mass spectrometry. The certificate is published under the batch number printed on the vial, and you can search the certificate of analysis library by that number.

For a blend, read the certificate component by component. It should confirm the identity of all four peptides, and a mass spectrum should show values consistent with the molar masses in the identifier table. Our guide on how to read a peptide certificate of analysis explains the HPLC trace, the mass spectrum and net peptide content.

KLOW is a market name for four peptides in one vial, and all of its science belongs to the parts: cell and rodent work for BPC-157, TB-500 and KPV, and small topical human studies for GHK-Cu. No study has tested the blend. In Australia the vial contains two Schedule 4 and Appendix D substances, and the same two are prohibited in sport. The batch certificate is the only document that shows what a particular vial contains.